Cancer and Trombosis: can we predict it?

EHA Library, Nick van Es, 221460

Listen to the patient

EHA Library, Fabio Efficace, 221459

What's new in CLL?

EHA Library, Michael Hallek, 221458

Expert interview with Carl June

EHA Library, Carl June, 221457

Expert interview with Marion Subklewe

EHA Library, Marion Subklewe, 225610

Expert interview with Sara Gorashian

EHA Library, Sara Gorashian, 225609

Expert interview with Jyoti Nangalia

EHA Library, Jyoti Nangalia, 225608

Normal and leukemic hematopoiesis in the bone marrow. Metabolic regulation in a dynamic environment

EHA Library, Tsvee Lapidot, 219244

Treating Thalassemia: Thinking 'out of the box'

EHA Library, Stefano Rivella, 219243

Amyloidosis: The rapidly changing face of diagnosis and therapy in AL amyloidosis

EHA Library, GIAMPAOLO MERLINI, 219242

ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY

EHA Library, Meletios Dimopoulos, 218888

CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Steffen Boettcher, 218887

THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB

EHA Library, Rocco Piazza, 218886

From epidemiology to treatment decisions (the role of T cell registries)

EHA Library, Massimo Federico, 219234

PTCL: Evidence for subtype specific treatment approaches?

EHA Library, F D'Amore, 219235

NK/T cell lymphoma: Novel insights, novel therapies?

EHA Library, Won Seog Kim, 219236

RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS

EHA Library, Jong Wook Lee, 218885

HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY

EHA Library, Lydia Scarfò, 218883

Mechanisms underlying oncogenic transcription factors in ALL

EHA Library, Jan Cools, 219226

MAPPING THE THREE-DIMENSIONAL GENOME DYNAMICS IN NORMAL AND NEOPLASTIC B CELLS

EHA Library, Iñaki Martin-Subero, 219220

THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB

EHA Library, Rocco Piazza, 219222

CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Steffen BOETTCHER, 219223

Single cell genomics in CML

EHA Library, Adam Mead, 219230

Future prospects for the treatment of hemophilia: A global perspective

EHA Library, David Lillicrap, 219238

Modified FVIII and FIX recombinant products

EHA Library, Elena Santagostino, 219240

Monoclonal antibody-based therapies

EHA Library, Midori Shima, 219239

TFR treatment goal for all CML patients

EHA Library, Delphine Rea, 219232

Immune targeting of CML to improve treatment outcome

EHA Library, Andreas Burchert, 219231

Current concepts in ALL frontline trials in children and young adults

EHA Library, Mats Heyman, 219228

Novel genetic subgroups in acute lymphoblastic leukemia

EHA Library, Christine Harrison, 219227

HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY

EHA Library, Lydia Scarfò, 219219

RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS

EHA Library, Jong Wook Lee, 219221

ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY

EHA Library, Meletios Dimopoulos, 219224

Treating thalassemia with iron restriction

EHA Library, Stefano Rivella, 223400

Is getting old bad?

EHA Library, Michael Heuser, 223399

CAR -T cell therapy: Here to say?

EHA Library, Peter Borchmann, 223398

The best treatment for SAA?

EHA Library, Jakob R Passweg, 223397

Anemia in the elderly: is it real?

EHA Library, Domenico Girelli, 223396

Iron Metabolism: what do you need to know?

EHA Library, Tomas Ganz, 223395

Marginal Zone Lymphona: from diagnosis to treatment

EHA Library, Catherine Thieblemont, 223394

Aspergillus resistance: Time to change the antifungal approach?

EHA Library, Katrien Lagrou, 219215

New immunomodulators - New infectious diseases mind set?

EHA Library, Sibylle Mellinghoff, 219214

Molecular characterization as a basis for novel treatment paradigms in AML

EHA Library, Hartmut Döhner, 219211

Towards a molecular classification of Philadelphia- negative myeloproliferative neoplasms

EHA Library, Radek Skoda, 219210

Precision hematology: Implementing genomic profiling at national level

EHA Library, Richard Rosenquist Brandell, 219209

Impact of underlying disease on secondary leukemia

EHA Library, Lene Sofie Granfeldt Østgård, 219206

Biology of secondary leukemia

EHA Library, Timothy Graubert, 219205

How I manage extramedullary disease and plasma cell leukemia

EHA Library, María-Victoria Mateos, 219203

Which are the preferred treatment combinations and sequence(s): In the transplant eligible / In the elderly

EHA Library, Hartmut Goldschmidt, 219201

One size does not fit all: Improving outcomes with personalized infection management?

EHA Library, Martin Hoenigl, 219216

Assessing MRD in multiple myeloma

EHA Library, Hervé Avet-Loiseau, 219212

Prognostic factors and treatment options in secondary leukemia

EHA Library, Maria Teresa Voso, 219207

What are the treatment goals and optimal endpoints in RRMM

EHA Library, Thierry Facon, 219202

Stem cell transplantation for myelofibrosis

EHA Library, Nicolaus Kröger, 219200

Inflammation and anti-inflammatory approaches in MPN

EHA Library, Steffen Koschmieder, 219199

Microenvironment in MPN

EHA Library, Simón Méndez-Ferrer, 219198

CHEMOTHERAPY AND VENETOCLAX IN ELDERLY AML TRIAL (CAVEAT): A PHASE 1B DOSE ESCALATION STUDY EXAMINING MODIFIED INTENSIVE CHEMOTHERAPY IN FIT ELDERLY PATIENTS

EHA Library, Andrew H. Wei, 214491

THE MUTATIONAL LANDSCAPE IN HYDROXYCARBAMIDE-RESISTANT/INTOLERANT ESSENTIAL THROMBOCYTHEMIA TREATED ON THE MAJIC-ET STUDY

EHA Library, Jennifer O'Sullivan, 214619

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIC PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME

EHA Library, Esther Natalie Oliva, 214478

OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PRIOR BLINATUMOMAB IN ZUMA-3, A STUDY OF KTE-C19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY

EHA Library, Olalekan O. Oluwole, 214484

THE FREQUENCY OF THE ETHNIC NEUTROPENIA-ASSOCIATED RS2814778 SNP OF DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) GENE IN A COHORT OF EUROPEAN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA

EHA Library, Helen Papadaki, 214588

NOVEL INSIGHTS INTO SPLEEN INJURY DURING THE FIRST 2 YEARS OF LIFE IN SCA CHILDREN: A LONGITUDINAL STUDY

EHA Library, Sara El Hoss, 214590

SINGLE-CELL PROFILING REVEALS KEY DIFFERENCES IN THE CELLULAR ARCHITECTURE OF HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS THROUGHOUT FETAL AND ADULT LIFE

EHA Library, Anindita Roy, 214591

TP53 MUTATION HAD A NEGATIVE PROGNOSTIC IMPACT IN UNTREATED YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AT HIGH-RISK: A SUB-ANALYSIS OF FIL-DLCL04 STUDY

EHA Library, Annalisa Chiappella, 214569

PRECLINICAL EVALUATION OF THE NEW BCMAXCD3 BISPECIFIC ANTIBODY JNJ-957 FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Kristine Frerichs, 214621

GENOMIC ALTERATIONS IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA FREQUENTLY AFFECT CELL CYCLE KEY REGULATORS AND NOTCH1 REGULATED TRANSCRIPTION.

EHA Library, Jennifer Edelmann, 214583

GROWTH DYNAMICS IN NATURALLY PROGRESSING CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Michaela Gruber, 214582

PHASE 1B/2 COMBINATION STUDY OF APR-246 AND AZACITIDINE (AZA) IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML)

EHA Library, David Sallman, 214477

DURABLE RESPONSE WITH VENETOCLAX IN COMBINATION WITH DECITABINE OR AZACITADINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Courtney D. DiNardo, 214482

PERSISTENT BCR-ABL1 CLONAL HEMATOPOIESIS AFTER BLAST CLEARANCE IDENTIFIES A CML-LIKE SUBGROUP OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ALL: INTERIM RESULTS FROM THE GRAAPH-2014 TRIAL

EHA Library, Emmanuelle Clappier, 214483

SIMULTANEOUS TARGETING OF MCL-1 (S63845) AND BCL-2 (VENETOCLAX) ANTI-APOPTOTIC PROTEINS IN MULTIPLE MYELOMA

EHA Library, Esperanza Algarín, 214498

PERIVASCULAR NICHE CELLS SENSE THROMBOCYTOPENIA AND ACTIVATE PLATELET-BIASED HSCS IN AN IL-1 DEPENDENT MANNER

EHA Library, Tiago Cunha Luis, 214499

GENOME WIDE ASSOCIATION STUDIES (GWAS) OF CEREBROVASCULAR EVENTS IN PATIENTS WITH SICKLE CELL ANAEMIA (SCA)

EHA Library, John Brewin, 214626

PROGNOSTIC FACTORS FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE

EHA Library, Rafal Machowicz, 214623

FAVOURABLE OUTCOMES WITH R-CODOX-M/R-IVAC ACROSS ALL SUBGROUPS OF AGGRESSIVE HIGH GRADE B-CELL LYMPHOMA: PATHOLOGY AND UPDATED SURVIVAL RESULTS FROM A PHASE 2 UK NCRI/LLR TRIAL

EHA Library, Elizabeth PHILLIPS, 214487

THE COMBINATION OF THE MDM2 ANTAGONIST, IDASANUTLIN WITH NILOTINIB TARGETS PRIMITIVE CHRONIC MYELOID LEUKEMIA (CML) CELLS IN VITRO AND IN VIVO.

EHA Library, Mary Scott, 214573

OVEREXPRESSION OF THE TRANSCRIPTION FACTOR CDX2 IN HAEMATOPOIETIC STEM CELLS PREDISPOSES TO HAEMATOLOGICAL MALIGNANCIES

EHA Library, Therese Vu, 214629

INTEGRATED ATAC-SEQ AND SINGLE-CELL SYNERGISTIC CHEMOSENSITIVITY PROFILING IDENTIFIES RATIONAL DRUG COMBINATIONS IN IBRUTINIB-TREATED CLL PATIENTS

EHA Library, Gregory Vladimer, 214638

1 INTRAVASCULAR HEMOLYSIS INDUCES COMPLEMENT SYSTEM ACTIVATION MEDIATED BY HEME AND HEME-LOADED ERYTHROCYTE MICROVESICLES

EHA Library, Lubka Roumenina, 214589

IMETELSTAT IN RBC TRANSFUSION-DEPENDENT (TD) LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESA) (IMERGE): UPDATED EFFICACY AND SAFETY

EHA Library, Pierre Fenaux, 214476

GENOME-WIDE ASSOCIATION STUDY REVEALS ANKYRIN REPEAT AND SOCS BOX PROTEIN 3 (ASB3) AND INOSITOL POLYPHOSPHATE MULTIKINASE (IPMK) AS NEW RISK LOCI FOR RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Laura Hinze, 214578

EFFECTS OF DARATUMUMAB ON THE COMPOSITION AND ACTIVATION STATUS OF IMMUNE-CELL POPULATIONS IN CENTAURUS, A PHASE 2 RANDOMIZED STUDY OF SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS

EHA Library, Homer Adams III, 214585

MANAGEMENT OF ELANE-NEUTROPENIA: LIFETIME G-CSF VS HAEMATOPOIETIC STEM CELL TRANSPLANTATION LEARNING LESSON FROM THE EXPERIENCE

EHA Library, Francesca Fioredda, 214587

MS4A3 REGULATES CELL SURFACE CYTOKINE RECEPTOR EXPRESSION, DIFFERENTIATION, AND DRUG RESISTANCE IN CHRONIC MYELOID LEUKEMIA

EHA Library, Anna Eiring, 214572

MUTANT IDH (MIDH) INHIBITORS, IVOSIDENIB OR ENASIDENIB, WITH AZACITIDINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Courtney D. DiNardo, 214481

IMPACT OF CONCURRENT FOLLICULAR LYMPHOMA OR OTHER LOW-GRADE B-CELL LYMPHOMA ON THE CLINICAL OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yucai Wang, 214618

SURVIVAL OF VERY ELDERLY PATIENTS WITH DLBCL ACCORDING TO TREATMENT INTENSITY IN THE RITUXIMAB ERA: A SWEDISH LYMPHOMA REGISTRY STUDY

EHA Library, Kristina Sonnevi, 214568

CHARACTERIZATION OF ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITORS OF COMPLEMENT C5

EHA Library, Alonso Ricardo, 214586

THE EFFECT OF COMPLEMENT INHIBITOR CP40 ON ERYTHROCYTE DESTRUCTION IN AIHA

EHA Library, Inge Baas, 214625

A NOVEL, INTEGRATED AND VALIDATED PROGNOSTIC INDEX FOR PREDICTING OUTCOME IN ACUTE LYMPHOBLASTIC LEUKAEMIA PROVIDES NEW APPROACH FOR RISK STRATIFICATION.

EHA Library, Anthony Moorman, 214577

JAK1-STAT3 SIGNALING AXIS SUPPORTS LEUKEMIC STEM CELL PERSISTENCE IN CML

EHA Library, Mirle Schemionek-Reinders, 214571

EXPRESSION OF PROTEINS IN CD138+ PLASMA CELLS PREDICTS PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VRD REGIMEN.

EHA Library, Irena Misiewicz-Krzeminska, 214584

P53 DEFICIENCY DRIVES LEUKEMIC TRANSFORMATION OF HEMATOPOIETIC STEM CELLS BY MAINTAINING QUIESCENCE IN RESPONSE TO DNA DAMAGE

EHA Library, Andreas Brown, 214628

A RANDOMIZED PHASE II STUDY OF STANDARD DOSE AZACITIDINE ALONE OR IN COMBINATION WITH LENALIDOMIDE IN HIGH-RISK MDS WITH A KARYOTYPE INCLUDING DEL(5Q)

EHA Library, Bengt Rasmussen, 214575

CLINICAL IMPORTANCE OF DNA METHYLATION SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS TREATED WITH CHEMO-IMMUNOTHERAPY

EHA Library, J.C. Strefford, 214580

ENASIDENIB MONOTHERAPY IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH PREVIOUSLY UNTREATED MUTANT-IDH2 (MIDH2) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Daniel A. Pollyea, 214480

RADIOTHERAPY TO BULKY AND EXTRALYMPHATIC DISEASE IN COMBINATION WITH 6XR-CHOP-14 OR R-CHOP-21 IN YOUNG GOOD-PROGNOSIS DLBCL PATIENTS: RESULTS OF THE 2X2 RANDOMIZED UNFOLDER TRIAL OF THE DSHNHL/GLA

EHA Library, Viola Pöschel, 214567

IVOSIDENIB (AG-120) IN MUTANT IDH1 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS OF A PHASE 1 STUDY

EHA Library, Daniel A. Pollyea, 214479

THE TUMOR SUPPRESSOR MIR-300 PRESERVES CANCER STEM CELLS AND INHIBITS NK CELL ANTICANCER IMMUNITY

EHA Library, Danilo Perrotti, 214570

A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME

EHA Library, Guillermo Garcia-Manero, 214574